Radiotherapy and Bevacizumab for intramedullary and leptomenigeal metastatic Glioblastoma: a case report and review of the literature.
Summary of "Radiotherapy and Bevacizumab for intramedullary and leptomenigeal metastatic Glioblastoma: a case report and review of the literature."
Abstract Glioblastoma (GBM) developed metastases rarely and the prognosis, in these cases, was very poor. We reported a 30-year patient who, developing intramedullary and leptomeningeal metastases from GBM, underwent palliative spinal radiotherapy and Bevacizumab.
1Department Radiotherapy Oncology, IRCCS/CROB , Rionero in Vulture (PZ) , Italy.
This article was published in the following journal.
Name: The International journal of neuroscience
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22720749
- DOI: http://dx.doi.org/10.3109/00207454.2012.704456
Medical and Biotech [MESH] Definitions
Spinal Cord Neoplasms
Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.
Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
The total amount of radiation absorbed by tissues as a result of radiotherapy.
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
The purpose of this case series is to report the unexpected occurrence of four cases of late radiation-induced neurotoxicity with bevacizumab use following radiotherapy to the CNS. We retrospectively...
The authors report a case of temporal glioblastoma multiforme, who received post-operative radiotherapy. The patient presented to neurosurgery 8 months post-radiotherapy with CSF otorrhoea. This was s...
Background Recurrent glioblastoma is nearly always fatal, with median survival rates of approximately 12-14 months. Previous phase II clinical trials showed promising results with bevacizumab, alone...
Bevacizumab is expected to constitute a new treatment modality for radiation necrosis. In the present cases, we observed a recurrence of radiation necrosis after temporary improvement by bevacizumab t...
We now describe the first example of a patient who developed perirenal hematoma during the course of bevacizumab-containing chemotherapy. A 59-years-old woman with metastatic rectal cancer treated wit...
This is a Phase II, open-label, multicenter, randomized, non comparative study consisting of two concurrent single-arms. Approximately 160 subjects will be randomized in a 1:1 ratio to Ar...
In this phase II trial the investigators plan to incorporate two targeted agents, bevacizumab and everolimus, into the first-line multimodality therapy of glioblastoma. In the first porti...
This is a phase II study of Bevacizumab plus Temodar and Tarceva in patients with non-progressive glioblastoma or gliosarcoma. Patients must have stable disease immediately following a sta...
Primary Objectives: - To determine the effectiveness of bevacizumab (Avastin) at 5 mg/kg every 3 weeks in combination with lomustine administered at 90 mg/m2, on day 3 of each 6-w...
The purpose of the this study is to see if an investigations cancer treatment called vorinostat can be combined with the irinotecan/bevacizumab regimen safely.